Skip to Main Content

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the ongoing layoffs. Despite the downsizing, there is movement. Here are some of the latest comings and goings. Recognize anyone?

And here is our regular feature in which we highlight a different person each week. This time around, we note that Merck KGaA hired Maya Martinez-Davis as global head of its oncology franchise. Most recently, she was regional president, North America, for oncology at Pfizer, where she spent nearly a decade in various senior roles.

Symic Bio hired Kathleen Gogas as vice president of preclinical development;


KemPharm hired Daniel Cohen as executive vice president, government and public relations;

KemPharm hired Rene Braeckman as vice president, clinical development;


Innocoll Holdings hired Dr. Lesley Russell as chief medical officer;

Melinta Therapeutics named Dr. Eugene Sun as chief executive officer;

Apollo Therapeutics hired Dr. Richard Butt as chief executive officer;

Pacira Pharmaceuticals hired Charles Reinhart III as chief financial officer;

Vernalis Therapeutics hired Sandy Sommer as president and chief operating officer;

CASI Pharmaceuticals hired James Goldschmidt as vice president of business development;

Profusa hired Bradley Rice as vice president of engineering R&D;

Nivalis Therapeutics hired Dr. David Rodman as chief medical officer and executive vp of discovery;

Millendo Therapeutics hired Thomas Hoover as vice president, commercial strategy;

Millendo Therapeutics hired Andrew Spencer as vice president, preclinical R&D;

Lumos Pharma hired Dr. David Weiner as chief medical officer;

Lumos Pharma hired John McKew as chief scientific officer;

Avion Pharmaceuticals hired Harold Deas as chief executive officer;

Aurinia Pharmaceuticals hired Charles Rowland to replace Stephen Zaruby as chief executive officer;

AMO Pharma hired Dr. Joseph Horrigan as chief medical officer;

AMO Pharma hired Alison McMorn as vice president of clinical operations;

AMO Pharma hired Bernard Kiernan as head of pharmaceutical sciences and manufacturing.

Comments are closed.